Department of Internal Medicine, Gaziosmanpasa University School of Medicine, 60200 Tokat, Turkey.
Department of Radiology, Gaziosmanpasa University School of Medicine, 60200 Tokat, Turkey.
Endocr Metab Immune Disord Drug Targets. 2020;20(6):952-958. doi: 10.2174/1871530320666200220125829.
Nonalcoholic fatty liver disease (NAFLD) is closely associated with metabolic syndrome (MetS), insulin resistance (IR) and chronic inflammation. Although familial Mediterranean fever (FMF) patients have no symptoms in the periods between attacks, their subclinical inflammation continues. The aim of the present study was to determine the NAFLD frequency in FMF patients and to evaluate their MetS, IR and lipid profiles.
The study included 54 FMF patients and 54 control subjects. The clinical and demographic characteristics of the subjects were recorded, and the patients' Pras disease severity score was calculated. IR was determined using the homeostasis model assessment (HOMA) index. MetS was diagnosed using the revised National Cholesterol Education Program Adult Treatment Panel III criteria (NCEP ATP III). Hepatic ultrasonography was used to diagnose NAFLD.
NAFLD was observed in 15 FMF patients (27.8%) and 14 controls (25.9%). The difference between the groups was not significant (p=0.828). Similarly, no significant difference was found between the two groups for MetS frequency and HOMA index levels. Fasting plasma glucose was significantly higher in FMF patients, whereas differences between the two groups were not significant for lipid levels and other parameters. When FMF patients with and without NAFLD were compared, no significant difference was found in Pras disease severity score, duration of the disease and daily colchicine dose.
The present study showed that NAFLD frequency was not increased in FMF patients, and that patients' MetS frequency, IR and lipid profiles were not different from control subjects.
非酒精性脂肪性肝病（NAFLD）与代谢综合征（MetS）、胰岛素抵抗（IR）和慢性炎症密切相关。虽然家族性地中海热（FMF）患者在发作之间没有症状，但他们的亚临床炎症仍在继续。本研究旨在确定 FMF 患者的 NAFLD 频率，并评估他们的 MetS、IR 和血脂谱。
本研究纳入了 54 名 FMF 患者和 54 名对照者。记录了受试者的临床和人口统计学特征，并计算了患者的 Pras 疾病严重程度评分。使用稳态模型评估（HOMA）指数来确定 IR。使用修订后的国家胆固醇教育计划成人治疗专家组 III 标准（NCEP ATP III）诊断 MetS。使用肝脏超声诊断 NAFLD。
在 15 名 FMF 患者（27.8%）和 14 名对照者（25.9%）中观察到 NAFLD。两组之间的差异无统计学意义（p=0.828）。同样，两组之间 MetS 频率和 HOMA 指数水平无显著差异。FMF 患者的空腹血糖明显升高，而两组之间的血脂水平和其他参数无显著差异。当比较有和没有 NAFLD 的 FMF 患者时，Pras 疾病严重程度评分、疾病持续时间和每日秋水仙碱剂量无显著差异。
本研究表明，FMF 患者的 NAFLD 频率没有增加，患者的 MetS 频率、IR 和血脂谱与对照者无差异。
